In addition to pHER2 and pEGFR, which were predictors of response to neratinib in HER2+ breast cancer and TNBC, Bim was noted to contribute to neratinib sensitivity, suggesting the induction of apoptosis as a mechanism of action in neratinib combination therapies. Here, BCL2L11 is linked to breast carcinoma.